Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced that the U.S. Food
and Drug Administration (FDA) has requested that Sarepta provide
dystrophin data, as measured by western blot, from biopsies already
obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as
part of its ongoing evaluation of the eteplirsen New Drug Application
(NDA). The Company plans to submit data from thirteen patient biopsy
samples, at baseline and Week 48, to the FDA over the coming weeks to
facilitate a prompt decision on the NDA by the Agency.
Return on Investment for Regulus Therapeutics Inc. (NASDAQ:RGLS) is -45.60% and on Tuesday its shares closed at $5.46. Regulus Therapeutics Inc. (NASDAQ:RGLS) monthly performance stands at 1.49% while its year to date performance is -37.39%.
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced top-line results from the primary endpoint analysis of one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza™.
The Michaels Companies, Inc. (NASDAQ:MIK) shares fell -8.13% on last trading day to close the day at $27.69. Company price to sale ratio is 1.17 and has 0.40% insider ownership. The Michaels Companies, Inc. (NASDAQ:MIK) belongs to Services sector.
The Michaels Companies, Inc. (NASDAQ:MIK) on Tuesday reported fiscal
first-quarter net income of $70.8 million. The Irving, Texas-based
company said it had net income of 34 cents per share. Earnings, adjusted
for non-recurring costs, came to 36 cents per share.
On last trading day Myriad Genetics, Inc. (NASDAQ:MYGN) advanced 0.81% to close at $34.76. MYGN is -6.49% away from its 52 week high and is moving 22.60% ahead of its 52 week low. Myriad Genetics, Inc. (NASDAQ:MYGN) return on investment (ROI) is 12.00% while return on equity (ROE) is 15.00%.
Myriad Genetics, Inc. (NASDAQ:MYGN) on Tuesday said its board approved an additional $200 million for its share buyback program. As of the end of its fiscal third quarter, the personalized medicine company said it repurchased more than $1.1 billion in stock since it started its buyback program in 2010, according to a news release.
Vale S.A. (NYSE:VALE) on Tuesday closed at $4.80. Stock institutional ownership is 15.60% while insider ownership includes 38.50%. Vale S.A. (NYSE:VALE) distance from 50-day simple moving average (SMA50) is 2.99%.
Moody’s Investors Service (“Moody’s”) assigned a Ba3 senior unsecured foreign currency rating to the proposed senior unsecured notes due 2021 to be issued by Vale Overseas Limited, which will be fully and unconditionally guaranteed by Vale S.A. (NYSE:VALE). Proceeds will be used for liability management and general corporate purposes. The outlook for the rating is negative.
Return on Investment for Regulus Therapeutics Inc. (NASDAQ:RGLS) is -45.60% and on Tuesday its shares closed at $5.46. Regulus Therapeutics Inc. (NASDAQ:RGLS) monthly performance stands at 1.49% while its year to date performance is -37.39%.
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced top-line results from the primary endpoint analysis of one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or Daklinza™.
The Michaels Companies, Inc. (NASDAQ:MIK) shares fell -8.13% on last trading day to close the day at $27.69. Company price to sale ratio is 1.17 and has 0.40% insider ownership. The Michaels Companies, Inc. (NASDAQ:MIK) belongs to Services sector.
On last trading day Myriad Genetics, Inc. (NASDAQ:MYGN) advanced 0.81% to close at $34.76. MYGN is -6.49% away from its 52 week high and is moving 22.60% ahead of its 52 week low. Myriad Genetics, Inc. (NASDAQ:MYGN) return on investment (ROI) is 12.00% while return on equity (ROE) is 15.00%.
Myriad Genetics, Inc. (NASDAQ:MYGN) on Tuesday said its board approved an additional $200 million for its share buyback program. As of the end of its fiscal third quarter, the personalized medicine company said it repurchased more than $1.1 billion in stock since it started its buyback program in 2010, according to a news release.
Vale S.A. (NYSE:VALE) on Tuesday closed at $4.80. Stock institutional ownership is 15.60% while insider ownership includes 38.50%. Vale S.A. (NYSE:VALE) distance from 50-day simple moving average (SMA50) is 2.99%.
Moody’s Investors Service (“Moody’s”) assigned a Ba3 senior unsecured foreign currency rating to the proposed senior unsecured notes due 2021 to be issued by Vale Overseas Limited, which will be fully and unconditionally guaranteed by Vale S.A. (NYSE:VALE). Proceeds will be used for liability management and general corporate purposes. The outlook for the rating is negative.
No comments:
Post a Comment